Current status of new agents.
D000505:Alopecia / Q000139:chemically induced; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D001375:Azaguanine / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010984:Platinum / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D003510:Cyclohexanes; D004338:Drug Combinations; D009607:Nitrosourea Compounds; D010984:Platinum; D001374:Azacitidine; D001375:Azaguanine; D002330:Carmustine; D011241:Prednisone